In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 169-171

  Pfaller, M A ^a   Zhang, J ^a   Messer, S A ^a   Brandt, M E ^b   Hajjeh, R A ^b   Jessup, C J ^c   Tumberland, M ^d   Mbidde, E K ^e   Ghannoum, M A ^c  

^a UNIVERSITY OF IOWA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UGANDA CANCER INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

AFRICA; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

EID: 0032937122     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.169     Document Type: Article

References (24)

1. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,246] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
2. Belanger, P., C. C. Nast, R. Fratti, H. Sanati, and M. Ghannoum. 1997. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1840-1842.
3. Berg, J., C. J. Clancy, and M. H. Nguyen. 1998. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186-187.
4. Brandt, M. E., L. C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, R. W. Pinner, and the Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J. Clin. Microbiol. 34:912-917.
5. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, E. A. Graviss, J. Rees, E. D. Spitzer, R. W. Pinner, L. W. Mayer, and the Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. J. Infect. Dis. 174:812-820.
6. Dismukes, W. E. 1988. Cryptococcal meningitis in patients with AIDS. J. Infect. Dis. 157:624-628.
7. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
8. Hajjeh, R. A., M. E. Brandt, and R. W. Pinner. 1995. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol. Rev. 17:303-320.
9. Heyderman, R. S., I. T. Gangaidzo, J. G. Hakim, J. Mielke, A. Taziwa, P. Musvaire, V. J. Robertson, and P. R. Mason. 1998. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin. Infect. Dis. 26:284-289.
10. Kwon-Chung, K. J., and J. E. Bennett. 1992. Medical mycology. Lea & Febiger, Malvern, Pa.
11. Marco, F., M. A. Pfaller, S. Messer, and R. N. Jones. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42:161-163.
12. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, Jr., and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
13. Mitchell, T. G, and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
14. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
16. Paugam, A., J. Dupouy-Camet, P. Blanche, J. P. Gangnenux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
17. Powderly, W. G. 1993. Cryptococcal meningitis and AIDS. Clin. Infect. Dis. 17:837-842.
18. Powderly, W. G., M. S. Saag, G. A. Cloud, P. Robinson, R. D. Meyer, J. M. Jacobson, J. R. Graybill, A. M. Sugar, V. J. McAuliffe, S. E. Follansbee, C. U. Tuazon, J. J. Stern, J. Feinberg, R Hafner, W. E. Dismukes, NIAID AIDS Clinical Trials Group, and NIAID Mycoses Study Group. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:793-798.
19. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. T. Frame, W. He, C. M. van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. A. Waskin, T. M. Hooton, N. E. Hyslop, S. A. Spector, and S. A. Bozzette. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
20. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
21. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
22. Saag, M. S., G. C. Cloud, J. R. Graybill, J. Sobel, C. Tuazon, B. Wiesinger, L. Riser, B. L. Moskovitz, W. E. Dismukes, and the NIAID Mycoses Study Group. 1995. Comparison of fluconazole (FLU) versus itraconazole (ITRA) as maintenance therapy of AIDS-associated cryptococcal meningitis (CM), abstr. 1218, p. 244. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Sanati, H., S. A. Messer, M. Pfaller, M. Witt, R. Larsen, A. Espind-Ingroff, and M. Ghannoum. 1996. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J. Clin. Microbiol. 34:1280-1282.
24. van der Horst, C. M., M. S. Saag, G. A. Cloud, R. J. Hamill, J. R. Graybill, J. D. Sobel, P. C. Johnson, C. U. Tuazon, T. Kerkering, B. L. Moskovitz, W. G. Powderly, W. E. Dismukes, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.